Short ReportSleep and Breathing After Nusinersen Therapy in a Child With Spinal Muscular AtrophyKouri, Ioanna MD*; Demirel, Nadir MD†; Haile, Dawit T. MD†,‡; Selcen, Duygu MD†,§; Kotagal, Suresh MD*,†,§ Author Information *Center for Sleep Medicine, Mayo Clinic, Rochester, MN; †Department of Pediatric Adolescent Medicine, Mayo Clinic, Rochester, MN; ‡Department of Anesthesiology and Perioperative Medicine, Mayo Clinic, Rochester, MN; and §Department of Neurology, Mayo Clinic, Rochester, MN. Reprints: Ioanna Kouri, MD, Center for Sleep Medicine, Mayo Clinic, 200 First St SW, Rochester, 55905 MN (i[email protected]). The authors report no conflicts of interest. Journal of Clinical Neuromuscular Disease: December 2020 - Volume 22 - Issue 2 - p 105-108 doi: 10.1097/CND.0000000000000304 Buy Metrics Abstract Background: Spinal muscular atrophy (SMA) type 3 is an autosomal recessive neurological disorder associated with a deletion/mutation in the survival motor neuron gene, with gradually progressive degeneration of the motor neurons of the spinal cord and brainstem, which causes muscle weakness responsible for impairment of swallowing, breathing, and mobility. Report of case: We report an 11-year-old girl with SMA type 3 with moderate to severe obstructive sleep apnea (OSA) syndrome refractory to adenotonsillectomy and noninvasive ventilatory support. She was started on nusinersen, which is a novel disease modifying therapy for SMA. This new treatment led to improvement of the OSA in a short period, likely from better respiratory muscle function. Conclusions: The improvement in OSA supports the role of nusinersen in sleep-related upper respiratory muscle function in SMA type 3. Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.